# PT Bio Farma clinical trials: 47 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 47 trials with PT Bio Farma as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by PT Bio Farma: 47 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/pt-bio-farma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 47
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 47, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929285 | Cy-Tb for Detecting Mycobacterium Tuberculosis Infection in Indonesian Population | PT Bio Farma | Not applicable | Not yet recruiting | TB Infection | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929285) |
| October 2, 2026 | NCT07854847 | Study Interchangeability Hep-B Vaccine Administered at Birth Dose | PT Bio Farma | Phase 3 | Not yet recruiting | Vaccination Adverse Event, Immunogenicity, Vaccine | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854847) |
| September 17, 2026 | NCT07824310 | Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children | PT Bio Farma | Phase 3 | Not yet recruiting | Human Papillomavirus (HPV) Infection | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824310) |
| June 15, 2026 | NCT07647107 | A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations | PT Bio Farma | Phase 1 | Recruiting | Tuberculosis, TB Infection | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647107) |
| April 10, 2025 | NCT06921460 | Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV | PT Bio Farma | Observational | Not yet recruiting | Antibody Typhoid Vaccine | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06921460) |
| November 15, 2024 | NCT06690515 | Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants | PT Bio Farma | Phase 1/2 | Unknown | Vaccine Adverse Reaction, Vaccine Reaction | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06690515) |
| November 15, 2024 | NCT06690502 | Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination | PT Bio Farma | Observational | Completed | COVID-19 | 1,208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06690502) |
| November 2, 2023 | NCT06114641 | Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients | PT Bio Farma | Phase 4 | Completed | Safety Issues, Effect of Drug | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06114641) |
| November 1, 2023 | NCT06111911 | Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma) | PT Bio Farma | Not applicable | Completed | Human Papilloma Virus Infection | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06111911) |
| September 26, 2023 | NCT06053853 | Post Marketing Surveillance of Diphtheria Antitoxin (DAT) | PT Bio Farma | Phase 4 | Completed | Safety Issues | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06053853) |
| August 23, 2023 | NCT06006858 | Post Authorization Safety Study Moderna COVID-19 Primary Vaccine | PT Bio Farma | Observational | Completed | COVID-19 | 1,284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06006858) |
| July 6, 2023 | NCT05933278 | Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine | PT Bio Farma | Phase 2 | Completed | COVID-19 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05933278) |
| February 14, 2023 | NCT05727215 | Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age | PT Bio Farma | Phase 2 | Completed | COVID-19 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05727215) |
| December 20, 2022 | NCT05657769 | Preventive Care System Application Effectiveness Study on the Treatment of Diabetic Patients in Bandung | PT Bio Farma | Not applicable | Unknown | Diabetes Mellitus, Type 2 | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05657769) |
| September 19, 2022 | NCT05546502 | Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children | PT Bio Farma | Phase 3 | Completed | Vaccine Reaction, Vaccine Adverse Reaction | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05546502) |
| September 1, 2022 | NCT05525208 | Booster Study of COVID-19 Protein Subunit Recombinant Vaccine | PT Bio Farma | Phase 2 | Completed | COVID-19 | 696 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05525208) |
| August 1, 2022 | NCT05482295 | Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) | PT Bio Farma | Phase 3 | Not yet recruiting | Vaccine Reaction, Vaccine Adverse Reaction | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05482295) |
| August 1, 2022 | NCT05482282 | Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) | PT Bio Farma | Phase 3 | Withdrawn | Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction, Pertussis Vaccine Adverse Reaction, Haemophilus... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05482282) |
| June 27, 2022 | NCT05433285 | Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine | PT Bio Farma | Phase 3 | Completed | COVID-19 | 4,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05433285) |
| April 6, 2022 | NCT05313035 | Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine | PT Bio Farma | Phase 2/3 | Completed | COVID-19 | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05313035) |
| February 8, 2022 | NCT05228613 | Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018 | PT Bio Farma | Phase 1 | Completed | COVID-19 | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05228613) |
| November 17, 2021 | NCT05124340 | Safety and Tuberculin Conversion Following BCG Vaccination | PT Bio Farma | Phase 2 | Completed | BCG Vaccination Reaction | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05124340) |
| October 5, 2021 | NCT05067894 | Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine | PT Bio Farma | Phase 1 | Completed | Covid19 | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05067894) |
| September 8, 2021 | NCT05037227 | Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged \>18 Years in Indonesia | PT Bio Farma | Observational | Completed | Safety Issues | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05037227) |
| February 5, 2021 | NCT04741828 | Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian | PT Bio Farma | Phase 2/3 | Completed | Vaccine | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04741828) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 1 |
| Phase 2 | 8 |
| Phase 2/3 | 6 |
| Phase 3 | 11 |
| Phase 4 | 4 |
| Not applicable | 3 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 38 |
| Not yet recruiting | 5 |
| Unknown | 2 |
| Withdrawn | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 10 |
| Hepatitis B | 4 |
| Infections | 3 |
| Papillomavirus Infections | 2 |
| Virus Diseases | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Measles | 1 |
| Rubella | 1 |
| Tuberculosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
- [Social media agencies in the United States](https://specstream.ai/data/businesses/social-media-agencies/united-states)
- [Closet remodeling companies in the United States](https://specstream.ai/data/businesses/closet-remodeling-companies/united-states)
- [Mediators in the United States](https://specstream.ai/data/businesses/mediators/united-states)
- [Waterproofing contractors in the United States](https://specstream.ai/data/businesses/waterproofing-contractors/united-states)
- [Estate planning law firms in the United States](https://specstream.ai/data/businesses/estate-planning-law-firms/united-states)
